The research team, led by Julia Ayumi Ikeda Kawasaki of the State University of Londrina and Roberta Losi Guembarovski, focused on non-muscle-invasive bladder cancer, which accounts for roughly 75 percent of all cases. This category of the disease is notoriously frustrating to manage: recurrence rates range from 15 to 61 percent within the first year after resection and climb to 38 to 78 percent within five years. Despite these sobering figures, the field has struggled to identify robust prognostic biomarkers capable of flagging high-risk patients early, which is precisely why the researchers turned their attention to the genetics of apoptosis, the cellular self-destruct program that cancer cells must evade to survive.

BCL-2 sits at the heart of that evasion strategy. The protein it encodes is stationed on the outer mitochondrial membrane, where it binds to BAX, a pro-death protein, and thereby prevents the release of cytochrome C — the molecular trigger that would otherwise activate cytoplasmic caspases and dismantle the cell from within. When BCL-2 is overexpressed, malignant cells become effectively immortal, shrugging off the internal alarms that should spell their doom. The two variants examined in the study are single nucleotide polymorphisms, or SNPs: rs2279115, a G-to-T substitution located within the P2 promoter region of the gene, and rs3943258, a T-to-C substitution in an intronic segment previously shown to interact with histone marks such as H3K4me1 and H3K27ac, which influence chromatin accessibility and gene transcription.

To probe the functional significance of these variants, the team analyzed tissue samples and clinical data from 80 patients treated at the Londrina Cancer Hospital, dividing them into three groups: 19 with muscle-invasive tumors, 30 with non-muscle-invasive tumors that recurred, and 31 with non-muscle-invasive tumors that did not. Genomic DNA was extracted from buffy coat fractions of blood samples and genotyped using real-time PCR allelic discrimination assays on a StepOnePlus system, with TaqMan probes specific to each variant. Haplotype frequencies — the combinations of alleles inherited together on the same chromosome — were inferred with a Bayesian algorithm implemented in PHASE software, and only haplotypes exceeding 5 percent frequency were retained for statistical analysis to avoid the pitfalls of sparse data.

Protein expression was assessed through indirect immunohistochemistry on formalin-fixed, paraffin-embedded tissue blocks obtained by transurethral resection, with a board-certified pathologist scoring staining intensity as absent, weak, or strong in a blinded fashion. Palatine tonsil tissue and infiltrating lymphocytes served as positive controls, while selected samples were also examined by immunofluorescence to visualize weak and strong BCL-2 staining patterns directly. Across all malignant tissues, the protein localized exclusively to the cytoplasm of tumor cells, and most samples showed either absent or weak expression, prompting the researchers to pool weak and strong cases into a single positive-expression group for statistical power.

The genotyping results were striking. For rs2279115, the heterozygous GT genotype predominated at 53.8 percent of the cohort, while the wild-type GG genotype was least common at 21.3 percent. Statistical modeling revealed that this variant was significantly associated with positive BCL-2 expression: the TT genotype showed a significant link in the genotypic model (p = 0.035; OR 0.272) and the GT genotype in the overdominant model (p = 0.045; OR 0.398), suggesting that the presence of the T allele drives protein production. This finding fits neatly with the variant’s location in the P2 promoter region, where the T allele is thought to relieve transcriptional repression, and it echoes earlier reports that the TT genotype elevates BCL-2 levels in breast cancer patients. In contrast, the intronic rs3943258 variant showed no significant association with immunostaining in this cohort, leaving its functional role in bladder tissue an open question.

Perhaps the most consequential discovery emerged from haplotype analysis. Four haplotypes were inferred across the two SNPs — CG at 26.78 percent, TT at 28.22 percent, TG at 21.34 percent, and CT at 23.66 percent — and the CT combination turned out to be a significant risk factor for high-grade tumors. Patients carrying CT in either homozygous or heterozygous form faced roughly a threefold increase in the odds of harboring a high-grade malignancy (p = 0.020; OR 3.221; 95 percent CI 1.201 to 8.642), an effect that persisted after adjusting for biological sex, age, and smoking status. Because high histological grade signals a less favorable clinical outcome, this genetic signature could eventually help clinicians identify patients who warrant closer surveillance at the time of diagnosis. Notably, the researchers report that this specific haplotype-grade association has not been previously described.

Not every result pointed toward clinical utility, however. Kaplan-Meier survival analyses of recurrence-free survival — based on time-to-event data from 75 patients, including 37 recurrence events — showed no significant differences according to BCL-2 immunostaining intensity, TG haplotype status, or TT haplotype status. Cox proportional hazards models confirmed that neither staining intensity nor either haplotype profile was associated with the hazard of tumor recurrence, and exploratory interaction tests found no evidence that the effect of protein expression on survival depended on haplotype carrier status. The cohort itself was also largely unremarkable in its demographic risk profile: mean age was 69.55 years, 73.8 percent of patients were male, and 65 percent were non-smokers, but none of these variables showed a significant statistical association with muscle invasion or recurrence.

The authors are candid about the limitations of their work. The study was retrospective, long-term follow-up data were unavailable for survival analysis, and detailed treatment records — including tumor multiplicity, completeness of resection, intravesical therapy regimens, and surveillance intervals — were accessible for only a minority of patients, restricting the multivariable models. The sample size of 80 may also have underpowered the genetic analyses of individual polymorphisms against prognostic parameters, and nominal p-values were reported without formal correction for multiple comparisons, framing the findings as hypothesis-generating rather than definitive. Still, the team argues that the cohort size was well suited to the meticulous immunostaining work, and that the integrated approach — combining genotyping, haplotype reconstruction, and protein-level analysis — represents a methodological strength.

The bigger picture is one of cautious optimism. The study is, according to its authors, the first to investigate the interplay between BCL-2 allelic variants, haplotypic structures, and immunostaining profiles in urothelial bladder carcinoma, and it reinforces a growing consensus that combinations of SNPs — rather than single variants in isolation — may shape cancer biology in tissue-specific ways. Analogous BCL-2 haplotypes have been linked to leukemia susceptibility, lung cancer risk, and mortality outcomes, underscoring how context-dependent these genetic effects can be. If prospective studies in larger, fully annotated cohorts validate the CT haplotype as a marker of tumor aggressiveness and confirm the mechanistic link between the rs2279115 T allele and protein overexpression, BCL-2 profiling could one day serve as a complementary tool for risk stratification, helping urologists decide which patients need aggressive follow-up and which can be spared it. For now, the message is that the genetics of cell death may hold keys to predicting bladder cancer behavior — keys that are only beginning to turn.

Subject of Research: Association of BCL-2 gene polymorphisms and haplotypes with protein expression and clinical outcomes in urothelial bladder carcinoma

Article Title: Impact of BCL-2 rs2279115 and rs3943258 variants on protein expression and clinical outcome of urothelial bladder carcinoma

Article References: Kawasaki, J. A. I., de Souza, A. P., Pontes, J. P. R., Serpeloni, J. M., de Oliveira, J. N., Vanzela, A. L. L., Terziotti, F., Martinez-Lopez, W., de Oliveira, K. B., & Guembarovski, R. L. (2026). Impact of BCL-2 rs2279115 and rs3943258 variants on protein expression and clinical outcome of urothelial bladder carcinoma. Molecular Biology Reports, 53(1), Article 1544. https://doi.org/10.1007/s11033-026-12697-8

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12697-8

Keywords: BCL-2, urothelial bladder carcinoma, single nucleotide polymorphism, haplotype, apoptosis, immunohistochemistry, tumor recurrence, biomarkers, cancer genetics, promoter variant, tumor grade, prognosis

Chief among those new options are tropomyosin receptor kinase (TRK) inhibitors, oral small-molecule drugs such as larotrectinib and entrectinib that are prescribed not on the basis of where a tumor arises or what it looks like under the microscope, but on whether it carries a fusion of one of the three NTRK genes. When NTRK1, NTRK2 or NTRK3 is rearranged with a partner gene, the resulting chimeric protein carries a tyrosine kinase domain that fires without its normal neurotrophin ligand, driving constant signaling through the MAPK, PI3K and PKC pathways and pushing cells toward malignant growth. TRK inhibitors block that constitutive activity, and in fusion-positive cancers they have produced striking responses with a side-effect profile that is mostly mild and reversible, dominated by neurologic effects such as ataxia, dizziness, appetite increase and paresthesia—a consequence of the receptors’ normal role in nerve cells.

The catch is that nobody knew how often NTRK fusions occur in rhabdomyosarcoma. That gap is what motivated a team at Semmelweis University in Budapest to systematically map TRK protein expression across fifteen years of pediatric rhabdomyosarcoma cases, and their findings, published in Pathology and Oncology Research, deliver a sobering lesson about the limits of a popular screening shortcut. The study, led by Renáta Lajti of the Pediatric Center together with colleagues from the Department of Pathology and Experimental Cancer Research, examined samples from all 45 children treated for rhabdomyosarcoma at the center between 2007 and 2022, including patients diagnosed elsewhere. The cohort was nearly evenly split by sex, with a median age at diagnosis of just four years, and more than three-quarters of the children fell into the high-risk, very-high-risk or metastatic categories of the CWS 2012 treatment guidelines used in Hungary.

The researchers chose immunohistochemistry as their first-line screen, staining 4-micrometer sections from formalin-fixed, paraffin-embedded blocks with the Ventana pan-TRK (EPR17341) antibody, which recognizes a conserved C-terminal region shared by all three TRK proteins. The staining was run on a fully automated Leica BOND-MAX platform with heat-based epitope retrieval, and the digitized slides were scored by the percentage of tumor cells showing positivity: samples with at least 1 percent stained cells counted as positive, a deliberately low threshold chosen to maximize sensitivity, with intensity graded as mild (1 to 50 percent of cells), moderate (50 to 75 percent) or strong (more than 75 percent). Hematoxylin-eosin stains on adjacent sections ensured that expression was evaluated specifically in neoplastic cells rather than surrounding tissue—an important control, since the antibody cannot distinguish wild-type TRK protein from any abnormal form.

The headline result was that pan-TRK expression turned up in 17 of the 45 cases, or 38 percent of the cohort. Far more striking, however, was where that positivity concentrated. Histological subtype was the only clinicopathological feature showing a statistically significant association with TRK expression: 7 of the 8 alveolar rhabdomyosarcomas—the unfavorable subtype linked to PAX3/FOXO1 or PAX7/FOXO1 fusions and a more aggressive clinical course—were TRK-positive, compared with just 27 percent of the favorable-histology group. No significant correlations emerged with sex, age, tumor size, tumor site, lymph node status, primary metastasis, risk group, recurrence or survival. Staining was predominantly cytoplasmic, seen in 94 percent of positive cases, with nuclear and membrane positivity each appearing in about a third.

That subcellular pattern produced the study’s most unexpected finding. When the team dichotomized the staining patterns into a purely cytoplasmic group and a complex group involving nuclear or membrane components, they found a statistically significant association with tumor recurrence: every non-recurrent tumor in the cohort showed exclusively cytoplasmic TRK localization, while all four recurrent tumors fell into the complex category. The authors caution that this association has not been described before, cannot be tied to specific fusion partners without molecular confirmation, and may simply reflect the small number of cases—but they note it fits with emerging evidence from prostate and colorectal cancer showing that the subcellular compartmentalization of proteins can serve as an independent prognostic indicator.

Then came the disappointment at the heart of the paper. Because immunohistochemical positivity can reflect not only NTRK fusions but also wild-type overexpression or other genetic changes, the researchers subjected all 17 positive cases to confirmatory molecular testing: fluorescence in situ hybridization with break-apart probes for all three NTRK genes in 14 cases, and next-generation sequencing with the TruSight Oncology 500 panel—which covers 523 genes and detects fusions through its RNA component—in 5 cases, with two patients tested by both methods. In four cases, FISH could not be evaluated, presumably because of degraded nucleic acid in the long-archived tissue. But in every test that produced a result, the answer was the same: no NTRK fusion, no pathogenic point mutation, no copy number variation. The pan-TRK immunohistochemistry, in other words, had a positive predictive value of exactly zero for detecting actionable NTRK fusions in this cohort.

The result is less surprising in light of the broader literature than it is sobering. A recent meta-analysis reported an overall false-negative rate of 18 percent for pan-TRK immunohistochemistry across solid tumors, with NTRK3 fusions escaping detection most often, and both the sensitivity and specificity of the stain have been shown to be particularly poor in sarcomas. Prior studies of various sarcoma subtypes had already found that immunohistochemical positivity corresponds to a true fusion in only a minority of cases, but no one had systematically examined the question in pediatric rhabdomyosarcoma before. The Budapest team is, to their knowledge, the first to do so—and their data suggest that the low specificity seen across sarcomas extends to this tumor type as well.

Does this mean the staining is useless? Not quite, the authors argue. Immunohistochemistry remains far cheaper and more widely available than genetic testing, and in a tumor where the baseline prevalence of NTRK fusions is unknown, a cheap first-pass screen still has a logic—provided that no one treats a positive stain as sufficient grounds for prescribing a TRK inhibitor. Increased TRK expression can arise from point mutations or amplifications for which inhibitor efficacy has never been clinically demonstrated, and the drugs are approved only for fusion-positive disease. Genetic confirmation by FISH or next-generation sequencing remains the gold standard, and any patient whose molecular test does confirm an NTRK fusion becomes a genuine candidate for targeted therapy at relapse or progression.

The point was driven home, fittingly, by a case that fell just outside the study window. During the course of the work, the same institution encountered a pediatric rhabdomyosarcoma in which strong pan-TRK staining was confirmed by all three modalities in sequence: FISH revealed rearranged NTRK3 signals with the split pattern indicating a gene fusion, and next-generation sequencing corroborated the rearrangement. That child has been scheduled to receive TRK inhibitor therapy—a real-world demonstration of exactly the pipeline the study was designed to evaluate, in which an affordable immunostain flags a candidate and molecular testing seals the diagnosis. The authors’ conclusion is measured: pan-TRK immunohistochemistry is not an effective standalone pre-screen for NTRK fusions in pediatric rhabdomyosarcoma, but the unexpected link between subcellular TRK localization and recurrence hints at a second, prognostic life for the stain—one that larger, multicenter studies will now need to test.

Subject of Research: Pan-TRK immunohistochemistry and NTRK fusion testing in pediatric rhabdomyosarcoma

Article Title: TRK immunohistochemistry in pediatric rhabdomyosarcomas: diagnostic and prognostic utility and limitations

Article References: Lajti, R., Dezső, K., Sápi, Z., Papp, G., Mohás, A., Bukovszky, B., Szabó, S., Felkai, L., & Csóka, M. (2026). TRK immunohistochemistry in pediatric rhabdomyosarcomas: diagnostic and prognostic utility and limitations. Pathology & Oncology Research, 32, Article 1612374. https://doi.org/10.3389/pore.2026.1612374

Image Credits: AI Generated

DOI: 10.3389/pore.2026.1612374

Keywords: rhabdomyosarcoma, NTRK fusions, TRK inhibitors, immunohistochemistry, pediatric oncology, fluorescence in situ hybridization, next-generation sequencing, alveolar histology, targeted therapy, biomarker screening, tumor recurrence, Semmelweis University

The patient’s history is central to the case. Ten years earlier, he had undergone complete surgical excision of a basal cell carcinoma at another hospital with a 5-millimeter margin extending to the level of the subcutaneous tissue. Histopathological examination at that time had judged the surgical margins to be negative. Approximately one year before presentation at Kindai University Hospital, however, an erythematous plaque appeared at the same site and gradually enlarged. When the tumor was excised with what appeared to be adequate margins, the lesion was followed without further treatment, and it eventually recurred after a long interval.

At presentation, the clinical picture was deceptively simple. An ill-defined erythematous plaque measuring approximately 7 centimeters in diameter extended from the occipital region to the posterior neck, accompanied by a palpable subcutaneous nodule. Computed tomography showed a corresponding high-density lesion without lymph node enlargement or distant metastasis, and a skin biopsy confirmed recurrent basal cell carcinoma. The tumor was excised with a 1-centimeter margin, and the defect was reconstructed using a full-thickness skin graft.

Histopathological examination of the excised specimen revealed the technical crux of the case: infiltrative basal cell carcinoma with deep invasion and superficial lateral microextension extending beyond the clinically apparent lesion. The lateral margin was positive, and the minimum distance between the tumor and the deep surgical margin was only 0.5 millimeters. Infiltrative basal cell carcinoma is one of several histological subtypes in which tumor nests infiltrate in cord-like or micronodular patterns, which often obscure tumor boundaries both clinically and histopathologically.

Examination of the primary excision specimen showed that tumor nests were distributed predominantly within the subcutaneous tissue, with only limited continuity with the epidermis. Such a distribution may be difficult to recognize clinically as a superficial lesion and may lead to underestimation of tumor extent at the time of initial excision. Because the surgical margins had been judged negative, the lesion was followed without additional treatment, and the tumor eventually recurred after a long interval. The report suggests that this pattern of deep subcutaneous growth with limited epidermal continuity may explain why the tumor extent was difficult to appreciate clinically and why conventional margin determination based on surface findings was insufficient.

In the recurrent lesion, the tumor formed a nodular mass within the deeper subcutaneous tissue, suggesting a more aggressive growth pattern. At the same time, the tumor retained subtle lateral microextension within the superficial subcutaneous layer beyond the deep nodular component, making accurate margin determination difficult. Changes in skin coloration and a palpable subcutaneous nodule were used as clinical landmarks for estimating the tumor boundary; however, margin determination based solely on palpation was insufficient to capture the lateral tumor spread within the superficial subcutaneous layer.

To address this challenge, the surgical team employed a mapping biopsy strategy. Three weeks after the initial excision, mapping biopsies were performed at 13 sites to assess lateral tumor spread. The biopsies extended approximately 5 millimeters in depth to include the superficial subcutaneous tissue. Approximately 6 weeks later, additional excision was performed, with the resection boundary determined by connecting tumor-negative mapping biopsy sites. Histopathological examination confirmed complete tumor clearance, and no recurrence was observed at 6 months after the final excision.

Mohs micrographic surgery, a technique in which tumor is removed layer by layer with immediate microscopic examination of margins, is recommended for high-risk basal cell carcinoma. However, its availability varies among institutions. In retrospect, given the difficulty in clinically determining the tumor extent in this case, the authors suggest that temporary coverage with artificial dermis at the initial excision, followed by definitive reconstruction after histopathological confirmation of clear margins, might have been a reasonable alternative approach. In situations where Mohs surgery is not feasible, mapping biopsy may be useful for assessing tumor extent and guiding appropriate surgical margins.

The case underscores a broader principle in skin cancer surgery: histological subtype matters. In certain subtypes, including infiltrative basal cell carcinoma, tumor nests infiltrate in cord-like or micronodular patterns that often obscure tumor boundaries both clinically and histopathologically. It has also been reported that recurrent lesions may exhibit atypical patterns of tumor spread. The combination of deep nodular formation and superficial lateral microextension observed here represents one such atypical pattern, in which the clinically visible lesion substantially underestimated the true tumor extent in multiple directions.

For clinicians managing high-risk or recurrent basal cell carcinoma, the report offers a practical message. When tumor boundaries cannot be reliably determined clinically, particularly in infiltrative subtypes or recurrent lesions, surgeons should consider strategies that verify margins histopathologically before definitive reconstruction. Whether through Mohs micrographic surgery where available, temporary artificial dermis coverage pending margin confirmation, or mapping biopsy to delineate lateral spread, the goal remains the same: ensuring complete tumor clearance while avoiding unnecessary sacrifice of healthy tissue. In this case, a staged approach combining initial excision, systematic mapping biopsies, and definitive second excision achieved complete tumor clearance with no recurrence at 6 months.

Subject of Research: Recurrent infiltrative basal cell carcinoma with deep nodular formation and superficial lateral microextension

Article Title: Recurrent infiltrative basal cell carcinoma with deep nodular formation and superficial lateral microextension

Article References: Maeda, M., Yamamura, Y., Fujii, K., Nishimura, K., Usui, S., & Otsuka, A. (2026). Recurrent infiltrative basal cell carcinoma with deep nodular formation and superficial lateral microextension. Journal of Cutaneous Immunology and Allergy, 9, Article 17511. https://doi.org/10.3389/jcia.2026.17511

Image Credits: AI Generated

DOI: 10.3389/jcia.2026.17511

Keywords: basal cell carcinoma, skin cancer, tumor recurrence, mapping biopsy, surgical margins, infiltrative growth, Mohs surgery, dermatology, case report, subcutaneous invasion, Recurrent, infiltrative

The tracer at the heart of the study is O-(2-[18F]fluoroethyl)-L-tyrosine, commonly abbreviated as FET. Unlike the gadolinium-based contrast agents used in routine MRI, which highlight regions where the blood-brain barrier has broken down, FET is taken up by tumor cells through amino acid transporters that are upregulated in glioma tissue. This means the PET signal reflects metabolic activity rather than vascular leakage, allowing clinicians to visualize infiltrating tumor cells that extend beyond the enhancing core seen on contrast-enhanced T1-weighted MRI. International guidelines from the European Association of Nuclear Medicine, the European Association of Neuro-Oncology and the RANO group have already endorsed amino acid PET for glioma imaging, but prospective data from North American centers integrating FET-PET directly into radiotherapy planning have remained scarce. FETSMaRT was designed to fill that gap.

The study design was deliberately rigorous for a pilot. Thirty patients, all scheduled to receive post-operative radiotherapy, underwent a combined FET-PET/MRI acquisition before starting treatment. Crucially, the radiation oncologist who delineated the standard MRI-based target volumes was blinded to the PET data. Only afterward did the team generate a second set of targets derived from the FET-PET/MRI information, enabling a head-to-head, volumetric comparison of gross tumor volumes, clinical target volumes and planning target volumes. The median age of the cohort was sixty years, seventy-seven percent had glioblastoma, the most aggressive grade 4 form, and sixty percent carried a methylated MGMT promoter, a molecular marker associated with better chemotherapy response. This composition mirrors the typical high-grade glioma population seen in major treatment centers.

The headline numbers are striking. Discordance between the MRI-based and PET-derived gross tumor volumes occurred in seventeen of thirty patients, or 56.7 percent, while discordance at the clinical target volume level affected fifteen of thirty patients, exactly half of the cohort. Across the entire group, the FET-PET/MRI-derived volumes were consistently and significantly larger than the MRI-based ones. The gross tumor volume averaged 43.6 cubic centimeters on PET compared with 38.6 cubic centimeters on MRI, a difference that reached a p-value below 0.0001. The clinical target volume averaged 119.2 versus 110.8 cubic centimeters, with a p-value of 0.0045, and the planning target volume averaged 171.1 versus 159.6 cubic centimeters, with a p-value of 0.0003. In plain terms, the metabolic footprint of these tumors was reliably bigger than what the anatomical images suggested.

That consistency matters because of how radiotherapy for glioblastoma is actually delivered. Under current practice, shaped radiation beams are aimed at a target volume that expands outward from the visible tumor to account for anticipated microscopic infiltration, typically reaching a dose of sixty gray in thirty fractions over six weeks alongside the chemotherapy drug temozolomide. This treatment framework, established by the landmark Stupp trials of 2005 and 2009, has changed little in its imaging foundation even as radiation delivery technology has become dramatically more precise. If the biological target is systematically drawn too small, the most advanced linear accelerators in the world will still miss tumor cells that were never contoured in the first place.

The patterns of treatment failure recorded in the study reinforce that concern. Among patients whose disease progressed, the failures were predominantly central, meaning the tumor recurred within or near the high-dose radiation field in 60 percent of cases. Central failure is the classic signature of tumor cells that received radiation but survived, and it suggests that even the treated volume may not have covered the full metabolically active extent of disease. Historical dosimetric studies going back to the late 1990s have documented similar central recurrence patterns after three-dimensional conformal radiotherapy, and the FETSMaRT data add a metabolic imaging dimension to that long-standing problem.

The researchers also examined whether the size of the volume discrepancy predicted how quickly patients progressed. In the glioblastoma subgroup of twenty-three patients, Kaplan-Meier and Cox proportional hazards analyses related the magnitude of gross tumor volume and clinical target volume discordance to time to progression. The direction of the association was consistent: patients with larger discordance values tended to progress sooner. However, in this small pilot cohort neither association reached statistical significance. The authors are careful on this point, describing the findings as hypothesis-generating exploratory data that justify a larger prospective trial rather than proof of a survival effect. Small sample size is the obvious limitation, and the study was funded by a grant from the Brain Tumor Foundation Canada precisely to build the case for that definitive trial, which is registered as NCT06499831.

The broader context makes the timing of this work significant. A multicentre randomized European trial known as GLIAA, reported in The Lancet Oncology, recently compared FET-PET-guided re-irradiation against contrast-enhanced MRI guidance in patients with recurrent glioblastoma, adding momentum to the idea that amino acid PET should guide radiation decisions. Meanwhile, a separate Canadian phase 2 trial called UNITED has explored MRI-guided adaptive radiotherapy for high-grade glioma, and the TROG 18.06 FIG study in Australia has been prospectively evaluating FET imaging in glioblastoma across multiple centers. Taken together, these efforts signal a field-wide reassessment of the anatomical imaging paradigm that has governed brain tumor radiotherapy for a generation, with metabolic imaging positioned as the likely successor.

What would change for patients if FET-PET/MRI were adopted into routine planning? The volumetric differences documented in FETSMaRT, on the order of five to twelve cubic centimeters depending on the target level, are large enough to alter dose distribution in clinically meaningful ways, particularly for tumors located near eloquent brain regions where expanding the target risks harming functional tissue. Hybrid PET/MRI scanners, which acquire both modalities in a single session with perfectly registered images, remove much of the logistical friction that historically made PET integration cumbersome. The study authors note that deidentified participant data and analysis code will be available on reasonable request, supporting independent verification and pooled analyses as the evidence base grows.

For the roughly 77 percent of the cohort facing glioblastoma, a disease with a median survival that has crept only modestly above the fifteen-month mark despite two decades of intensifying therapy, the promise of a more accurate target is not an incremental technicality. Every cubic centimeter of metabolically active tumor that escapes the radiation field is a potential seed of recurrence, and central failures remain the dominant pattern of relapse. FETSMaRT does not prove that PET-guided contours will extend survival, but it establishes with prospective, blinded, quantitative rigor that conventional MRI systematically underestimates the biological extent of high-grade glioma in more than half of patients. The stage is now set for the definitive randomized trial that the Toronto team argues their pilot data demand, one that could finally align the physics of modern radiotherapy with the biology of the tumors it is meant to eradicate.

Subject of Research: Comparison of 18F-FET-PET/MRI and MRI-based radiotherapy target volumes in high-grade glioma

Article Title: Volumetric discordance between ¹⁸F-FET-PET/MRI and MRI-based radiotherapy target volumes in high-grade glioma: a prospective pilot study (FETSMaRT)

Article References: Singnurkar, A., Sahgal, A., Lechtman, E., Lim-Fat, M.-J., Graham, S. J., Lipsman, N., Maralani, P., Pond, G., & Detsky, J. S. (2026). Volumetric discordance between ¹⁸F-FET-PET/MRI and MRI-based radiotherapy target volumes in high-grade glioma: a prospective pilot study (FETSMaRT). Journal of Neuro-Oncology, 180(1), Article 20. https://doi.org/10.1007/s11060-026-05831-w

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05831-w

Keywords: 18F-FET-PET, glioblastoma, high-grade glioma, radiotherapy planning, PET/MRI, target volume delineation, tumor recurrence, neuro-oncology, medical imaging, clinical trial, MGMT methylation, radiation oncology

The research, published in Nature, was led by scientists from The Jackson Laboratory, Yale University, and collaborators spanning ten countries. Drawing on data from the international Glioma Longitudinal Analysis Consortium, known as GLASS, the team analyzed tumors from 183 patients whose cancers were sampled both before treatment and again after recurrence. The samples were collected through more than 500 surgeries performed across North America, Europe, Asia, Australia and South America, allowing researchers to directly compare how the same tumors changed over time within individual patients.

The scale of the effort matters because IDH-mutant gliomas are rare. Individual institutions rarely accumulate enough paired samples to draw statistically meaningful conclusions about how these tumors evolve. “IDH-mutant gliomas are rare, which makes them challenging to study. Through this international collaboration, we were able to gather enough samples to characterize the most common ways each type of IDH-mutant glioma changes when it recurs,” said study author Frederick Varn, a JAX assistant professor who co-led the research. By pooling tumors from dozens of centers, the consortium could identify recurring patterns of evolution rather than isolated case anecdotes.

IDH-mutant gliomas primarily strike patients in their 30s and 40s, an age group in which a brain cancer diagnosis is particularly devastating. Although many patients live for years after diagnosis, these tumors almost always return, and when they do, they tend to stop responding to the treatments that initially held them in check. Understanding the genetic events that accompany that transition has been a central goal of the neuro-oncology field, because it may reveal vulnerabilities that could be targeted before resistance becomes entrenched.

The most striking findings emerged from comparing the two main subtypes of IDH-mutant glioma: oligodendroglioma and astrocytoma. Although both are defined by the same IDH mutation, the study showed that they follow sharply divergent evolutionary paths after treatment. Oligodendrogliomas tended to acquire new point mutations in genes that help drive tumor growth, adding fresh genetic damage one alteration at a time. Astrocytomas, by contrast, were far more likely to undergo large-scale chromosomal events, gaining and losing entire stretches of DNA as the disease progressed.

“Oligodendroglioma and astrocytoma are distinct tumor types, despite sharing the IDH mutation. This study shows that differences that exist when the tumor is first detected can set the stage for what happens after they are treated,” Varn said. In other words, the biology a tumor carries at diagnosis appears to shape the menu of evolutionary strategies available to it later. A tumor’s starting genome, in this view, is not merely a snapshot of its present state but a forecast of how it will respond to the selective pressures of therapy.

The treatment itself also left measurable marks. The chemotherapy drug temozolomide, a standard therapy for these tumors, appeared to leave distinct genetic fingerprints in recurrent tumors, a signature pattern of mutations that researchers could detect in the post-treatment samples. This observation underscores a growing theme in cancer genomics: therapy is not a neutral event but an evolutionary force, and the drugs used to control a tumor can actively shape the genetic changes it acquires as it fights back.

Crucially, some of the genetic changes observed at recurrence were associated with worse outcomes for patients. In astrocytomas, large-scale chromosomal abnormalities, including the duplication of entire sets of chromosomes and catastrophic events in which chromosomes broke apart and reassembled, were linked to shorter survival after recurrence. In oligodendrogliomas, new genetic changes that emerged as tumors returned, including alterations linked to uncontrolled cell growth, were likewise associated with poorer prognosis. These associations suggest that the mode of evolution is not just biologically interesting but clinically meaningful, potentially helping physicians identify which patients face the greatest risk once their disease returns.

The findings arrive at a moment of real momentum for the field. In 2024, the FDA approved vorasidenib, an IDH inhibitor, for certain patients with these tumors, marking a major therapeutic advance. While the new study focused specifically on the changes tumors undergo after radiation and chemotherapy rather than after IDH inhibition, its results can be applied to tailor treatment approaches to specific glioma types and to the genetic changes each type is likely to acquire as it evolves. A clinician who knows that an astrocytoma is prone to wholesale chromosomal upheaval, for example, may monitor and treat it differently than one facing an oligodendroglioma that accumulates targeted mutations.

“Our results and datasets provide a reference that helps understand how current and new therapies alter tumor behavior. Ultimately, we hope this will enable us to not just observe but to direct tumor behavior and make therapies more effective that way,” said Roel Verhaak, Ph.D., vice chair for research and professor of neurosurgery at Yale School of Medicine. That ambition, steering tumor evolution rather than merely documenting it, represents a shift in how researchers think about treating cancers that recur. The study was conducted through the GLASS Consortium with researchers from institutions across North America, Europe, Asia and Australia, and was funded by the National Institutes of Health along with additional public, philanthropic and institutional sources. For patients facing a disease that almost always returns, the work offers something concrete: a genetic map of what recurrence actually looks like, and a foundation for anticipating it.

Subject of Research: Genomic evolution of recurrent IDH-mutant gliomas

Article Title: What happens when brain tumors return? International study tracks genetic changes behind recurring cancers

Article References: What happens when brain tumors return? International study tracks genetic changes behind recurring cancers. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: glioma, IDH mutation, astrocytoma, oligodendroglioma, tumor recurrence, genomic evolution, temozolomide, GLASS Consortium, Jackson Laboratory, Yale University, Nature, treatment resistance

The randomized controlled trial, known as ROADS, was co-led by Jeffrey Weinberg, M.D., professor of Neurosurgery, and Thomas Beckham, M.D., Ph.D., assistant professor of CNS Radiation Oncology, both of MD Anderson. It is the first Phase 3 study to directly compare GammaTile cesium-131 collagen tile-based radiation therapy, abbreviated TBRT, against postoperative stereotactic radiation therapy, or SRT, which has long been the accepted standard following brain metastasis surgery. The trial was sponsored by GT Medical Technologies, Inc., the developer of the GammaTile device, which is cleared by the U.S. Food and Drug Administration.

The technology behind TBRT is elegantly simple in concept yet sophisticated in its radiobiology. GammaTile consists of small collagen tiles, each roughly the size of a postage stamp, embedded with evenly spaced seeds containing cesium-131, a radioactive isotope. After a neurosurgeon removes a brain metastasis, the tiles are essentially wallpapered onto the walls of the resulting surgical cavity. From that position, the seeds deliver a continuous, low-dose stream of therapeutic radiation over the course of several weeks, precisely targeting the cavity surface where residual microscopic tumor cells are most likely to linger after resection.

A critical advantage of this brachytherapy approach lies in its dose distribution. The radiation emitted by cesium-131 falls off very rapidly with distance, a property known as steep dose fall-off. This means that while the cavity lining receives an intensified, escalated dose capable of destroying microscopic disease, the surrounding healthy brain tissue is exposed to very little radiation. The collagen matrix itself is biocompatible and gradually breaks down in the body, allowing the treatment to be completed without any need for the patient to return for repeated radiation sessions.

The clinical results reported in the ROADS trial are striking by any measure. At the one-year mark, only 1.3 percent of patients treated with tile-based radiation therapy experienced a recurrence of their tumor at the surgical site, compared with 15.4 percent of patients who received standard postoperative stereotactic radiation. Weinberg emphasized the magnitude of this difference, noting that implanting the radioactive tiles at the time of surgery guarantees that patients receive their treatment immediately, along with focal dose escalation, thereby having a meaningful impact on local tumor control. From a patient standpoint, he explained, the trial shows nearly four times the length of local control and an increase in overall survival, a difference he described as massive rather than marginal.

Survival outcomes were equally compelling. Median overall survival, a key secondary endpoint of the trial, reached 42.5 months in the TBRT arm, more than double the 17.6 months observed in patients treated with standard stereotactic radiation. For a patient population in which every additional month of quality survival matters enormously, a gain of nearly two years represents a transformative shift in prognosis. Equally important, the improved outcomes did not come at the cost of increased toxicity. The trial found no differences in serious treatment-related side effects between the two groups, and the rate of radiation necrosis, a feared late complication of radiation therapy for brain metastases, was nearly identical between the TBRT and SRT arms, underscoring the safety profile of the implanted tiles.

Beyond efficacy and safety, TBRT offers a significant logistical advantage that may partly explain its survival benefit. Postoperative stereotactic radiation is typically scheduled weeks after surgery, and guidelines suggest it should occur within four weeks of resection to maximize effectiveness. Yet in real-world practice, patients often face postoperative complications, scheduling delays, and interruptions to systemic cancer therapies, and approximately 20 percent of patients ultimately fail to receive their planned postoperative SRT, with measurable compromise in their outcomes. With TBRT, the radiation is delivered in a single step during the operation itself, with most patients completing their cranial radiation in just one day, compared with a median of 32 days for those needing to arrange postoperative SRT. This rapid completion potentially allows patients to return to systemic treatments that control their broader disease much sooner.

Beckham highlighted this convenience factor as a surprising and welcome finding, noting that the results are dramatically better than current alternatives and provide improved patient convenience by helping patients move past the roadblock of a brain metastasis diagnosis more quickly. Being able to get patients over that roadblock and back to managing their overall cancer, he observed, appears to positively impact more than just the surgical outcome, something the research team had not anticipated to such a magnitude. The observation suggests that the benefits of immediate, embedded radiation extend beyond pure tumor biology into the practical realities of cancer care coordination.

The clinical context makes these findings especially significant. Brain metastases are a common and devastating complication of advanced solid tumors, arising in many patients with cancers such as lung cancer, breast cancer, and melanoma, and they can profoundly affect both treatment planning and prognosis. Surgery is typically reserved for larger or symptomatic metastases that cause pressure on the brain or neurological deficits. However, even with meticulous resection, microscopic tumor cells remain in the cavity wall, and without any adjuvant radiation, recurrence at the surgical site occurs 50 to 60 percent of the time. Stereotactic radiation therapy was developed precisely to address this risk, delivering highly focused, dose-escalated beams to destroy residual cells while sparing healthy tissue, but its dependence on postoperative scheduling has left a persistent gap in care.

The ROADS investigators hope their results will accelerate guideline adoption and broader clinical rollout of tile-based radiation therapy, potentially reshaping the management of brain metastases worldwide. Future research will explore how widely TBRT can be integrated into metastasis care and whether the technique holds promise for other tumor types beyond brain metastases. If the trial’s remarkable combination of superior tumor control, doubled survival, equivalent safety, and streamlined treatment logistics is confirmed in practice, the postage-stamp-sized tiles wallpapered into surgical cavities may well become a defining advance in neuro-oncology, offering patients with brain metastases not only more time but a faster, simpler path back to treating their cancer as a whole.

Subject of Research: Tile-based brachytherapy with cesium-131 for preventing recurrence of surgically resected brain metastases

Article Title: Researchers suggest tile-based radiation therapy as standard of care to lower risk of recurrence in brain metastases

Article References: Researchers suggest tile-based radiation therapy as standard of care to lower risk of recurrence in brain metastases. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: brain metastases, tile-based radiation therapy, GammaTile, brachytherapy, cesium-131, stereotactic radiation therapy, surgical resection, Phase 3 trial, MD Anderson Cancer Center, radiation necrosis, tumor recurrence, neuro-oncology

The team, led by corresponding author Chunshui Zhou, focused on a small molecule called SMIP004, a compound previously known to act on mitochondria, the energy-producing organelles inside cells. In a small-scale chemical screen run against senescent cancer cells, SMIP004 stood out for its ability to selectively kill TIS cells while sparing normally proliferating ones. That selectivity is the holy grail of senolytic drug development: any agent that clears senescent cells must not simultaneously damage healthy tissue or the still-vulnerable bulk of the tumor. Understanding why SMIP004 showed this preference became the central question of the study, and the answer led the researchers deep into the metabolic rewiring that defines the senescent state.

The key player turned out to be PDHA, the catalytic subunit of the pyruvate dehydrogenase complex, a mitochondrial enzyme that occupies one of the most important crossroads in cellular metabolism. Pyruvate, the end product of glycolysis, stands at a fork in the road: it can be converted to lactate in the cytoplasm, as happens in many cancer cells even in the presence of oxygen, or it can be funneled into the mitochondria by PDHA, feeding the citric acid cycle and oxidative phosphorylation. The researchers discovered that in therapy-induced senescent cancer cells, PDHA protein is unusually stable, and that this stabilization depends on elevated activity of AMPK, the AMP-activated protein kinase that serves as the cell’s master energy sensor. When energy is scarce, AMPK switches on catabolic programs and dials down anabolic ones; in senescent cells, the team found, AMPK activity keeps PDHA protected from degradation, effectively locking the senescent cells into a particular mitochondrial metabolic configuration.

SMIP004, remarkably, does not touch AMPK itself. Instead, the compound promotes the ubiquitin-mediated degradation of PDHA, stripping away the stabilized enzyme and collapsing the metabolic adaptation that senescent cells depend upon. The researchers demonstrated this relationship with elegant complementary experiments. When they activated AMPK with metformin, the widely used diabetes drug, proliferating cells began stabilizing ectopically expressed PDHA — and SMIP004 treatment could reverse that stabilization. Even more decisively, when the team mutated the AMPK phosphorylation sites on PDHA, the stabilization was abolished altogether. Together, these results establish a clean causal chain: AMPK activity stabilizes PDHA through its phosphorylation sites, and SMIP004 short-circuits that protection by pushing PDHA into the degradation machinery, independent of AMPK.

The consequences for senescent cancer cells are catastrophic. With PDHA destabilized, the cells’ mitochondrial metabolism falters, and at low doses SMIP004 induces what the authors describe as an energy crisis, culminating in massive apoptosis. Because senescent cells have become metabolically dependent on the AMPK–PDHA axis, they are far more vulnerable to this disruption than proliferating cells, which retain the flexibility to compensate. This dependency creates a therapeutic window: a dose of SMIP004 that leaves normal dividing cells largely unharmed can wipe out the senescent survivors that chemotherapy leaves behind. It is a textbook example of synthetic lethality emerging from a state-specific metabolic liability — the very principle that has driven success in other areas of targeted cancer therapy.

The most clinically compelling results came from mouse experiments. When the researchers combined SMIP004 with doxorubicin, a mainstay anthracycline chemotherapy drug, the combination suppressed tumor growth more effectively than chemotherapy alone, eliminated p21-positive cells — p21 being a canonical marker of senescence — and reduced metastatic lesions in tumor-bearing animals. This is precisely the outcome a senolytic strategy is designed to achieve: the cytotoxic drug generates the senescent population, and the senolytic agent clears it before those cells can contribute to relapse or spread. The finding that a senolytic can measurably reduce metastatic burden is particularly notable, since metastasis remains the leading cause of cancer mortality and is notoriously difficult to prevent with conventional approaches.

To explore the biology at single-cell resolution, the team performed single-cell RNA sequencing, which revealed that elevated transcription of PDHA is associated with senescence-like tumor cells. This observation ties the protein-level stabilization story to a broader transcriptional program: senescent tumor cells do not merely accumulate PDHA protein through post-translational protection, they also upregulate its expression, suggesting that the enzyme sits at the heart of the senescent phenotype rather than being an incidental passenger. The convergence of transcriptomic and biochemical evidence strengthens the case that PDHA is a genuine vulnerability of TIS cells and not an artifact of a single experimental system.

The human relevance of the findings received support from clinical tissue analysis. The researchers found that the expression of both PDHA and p21 is enhanced in tumors following chemotherapy, and that higher expression of these markers correlates with poor patient survival. In other words, the senescent population the study targets is not a laboratory curiosity — it appears in real patients after real treatment, and its presence tracks with worse outcomes. That correlation does not prove causation, but it is exactly the kind of biomarker evidence that justifies pursuing PDHA-targeted senolytics toward the clinic, and it suggests that PDHA and p21 could serve as pharmacodynamic markers to identify patients most likely to benefit from a combination regimen.

The study also carries broader implications for how scientists think about the metabolic identity of senescent cells. AMPK is often portrayed as a tumor-suppressive, health-promoting signal — metformin’s putative anti-cancer reputation rests partly on AMPK activation — yet this work shows that the same pathway can be co-opted by senescent tumor cells to stabilize a key metabolic enzyme and sustain their survival. The lesson is that context matters enormously: a pathway that protects healthy cells from metabolic stress may simultaneously protect damaged, treatment-altered tumor cells from elimination. It also highlights the value of unbiased chemical screening paired with proteomic analysis, an approach the team pursued with support from the Gygi laboratory’s proteomics expertise at Harvard, which can uncover mechanisms that hypothesis-driven work might never have targeted.

Considerable work remains before SMIP004 or any derivative could reach patients. The compound was identified in a small-scale screen, and its precise molecular target within the ubiquitin degradation machinery, its pharmacokinetic profile, and its safety in combination regimens all require further definition. Dosing in mice will need careful translation, and senolytics as a class raise questions about long-term effects, since senescent cells also play roles in wound healing and tissue repair. Still, the study delivers a complete conceptual arc: a defined metabolic dependency of therapy-induced senescent tumor cells, a small molecule that exploits it through a clearly delineated mechanism, and preclinical evidence that combining the compound with standard chemotherapy improves outcomes while reducing metastasis. If the AMPK–PDHA axis proves to be a general feature of senescent tumor cells across cancer types, the strategy described by Zhou and colleagues could become a template for a new generation of adjuvant therapies — drugs that do not attack the tumor directly, but instead clean up the dangerous residue that treatment leaves behind.

Subject of Research: Selective elimination of therapy-induced senescent tumor cells with the senolytic compound SMIP004 via blockade of AMPK-dependent PDHA stabilization

Article Title: Small mitochondria-targeting compound SMIP004 selectively eliminates therapy-induced senescent tumor cells by blocking AMPK-dependent PDHA stabilization and improves the outcomes of chemotherapy

Article References: Zhang, M., Piao, S., Song, Y., Zhao, N., Liu, A., Fu, S., Sun, W., Qiu, X., Zhang, J., Paulo, J. A., Yang, Y., Gygi, S. P., Xu, H., & Zhou, C. (2026). Small mitochondria-targeting compound SMIP004 selectively eliminates therapy-induced senescent tumor cells by blocking AMPK-dependent PDHA stabilization and improves the outcomes of chemotherapy. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03395-2

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03395-2

Keywords: senolytics, therapy-induced senescence, SMIP004, PDHA, AMPK, mitochondria, chemotherapy, doxorubicin, tumor recurrence, metastasis, p21, apoptosis

The starting point of the review is the physical assault that radiotherapy delivers. Ionizing radiation deposits energy that breaks DNA directly and, indirectly, floods cells with reactive oxygen species that damage proteins, lipids, and genomes alike. The dose, the fractionation schedule, and the type of radiation used all determine the character of this pressure. Cells that survive the initial insult do so by activating their DNA damage response machinery, a coordinated network of sensors, transducers, and effectors that pauses the cell cycle, repairs double-strand breaks through pathways such as non-homologous end joining and homologous recombination, and, when damage is overwhelming, triggers senescence or apoptosis. But the review emphasizes that DNA repair is only the first layer of a much deeper program of tolerance.

That deeper program is cellular plasticity. Rather than dying or fully recovering, a subset of surviving cells appears to enter altered, quasi-stable states that echo phenomena described in drug-treated tumors. The authors catalog several of these: persister-like states in which cells reversibly suspend proliferation; cancer stem cell-like states marked by molecules such as CD44 and aldehyde dehydrogenase, with enhanced self-renewal and repair capacity; senescence-like states, detectable in part by senescence-associated beta-galactosidase, in which cells remain metabolically alive but stop dividing and can secrete inflammatory signals; and hybrid epithelial-mesenchymal transition states that combine adhesive and migratory traits. Crucially, these states are not permanent identities. They are plastic, meaning the same residual cell may drift between them, and that fluidity makes them extraordinarily difficult to eliminate with any single targeted agent.

Alongside chromatin remodeling and transcriptional stress memory, which allow cells to carry a kind of biochemical recollection of the radiation they endured, these plastic states form the tumor-cell-intrinsic half of the radioresistance story. The review is careful to note that this intrinsic component complements rather than replaces classical radiosensitivity, which depends on factors such as oxygenation, cell-cycle phase, and repair capacity. What is new is the recognition that intrinsic tolerance alone cannot explain why recurrences so often emerge in predictable locations and time windows. For that, the authors argue, one must look outward, to the microenvironment that surrounds and stabilizes the surviving cells.

The concept of the tolerant niche is the conceptual heart of the paper. The authors describe several recurring microenvironmental configurations that act as sanctuaries for residual disease. Hypoxic niches are perhaps the best known: low oxygen reduces the radiation-induced free radical chemistry that makes oxygen so potent a radiosensitizer, and hypoxia simultaneously drives stem-like and invasive transcriptional programs. Perivascular niches, the zones around surviving blood vessels, shelter quiescent tumor cells and are rich in protective signaling. Niches dominated by cancer-associated fibroblasts and remodeled extracellular matrix provide both mechanical and biochemical support, secreting growth factors and stiffening tissue architecture in ways that dampen radiation lethality. Metabolic niches, shaped by nutrient scarcity and altered metabolite exchange, and myeloid niches, populated by tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells that suppress antitumor immunity, complete the picture. In each case, the niche does not merely coexist with tolerant cells; it actively maintains their state.

One of the review’s most useful contributions is its insistence that these mechanisms vary substantially among tumor types. The relative weight of hypoxia, stromal shielding, immune suppression, or stem-like plasticity differs between, for example, glioblastoma, pancreatic ductal adenocarcinoma, and lung cancer, and the authors caution against assuming that a strategy validated in one context will transfer to another. This heterogeneity has practical consequences for how the field measures residual disease. The authors assess the tools available and find them strikingly unequal in maturity. Functional imaging, including hypoxia-targeted PET tracers and advanced MRI sequences, and liquid biopsy based on circulating tumor DNA, offer selected clinical readouts that can already be deployed in trials to track residual disease and recurrence risk over time.

Spatial omics technologies, by contrast, which map gene expression and other molecular features across intact tissue sections, currently serve mainly as discovery and validation tools rather than clinical diagnostics. They are indispensable for identifying which cells occupy which niches and how those relationships change after irradiation, but sampling limitations, cost, and analytical complexity keep them out of routine practice. The review is candid about this gap: the field can describe tolerant niches in exquisite detail in resected specimens, yet it largely lacks the longitudinal, minimally invasive measurements needed to watch them form and dissolve in living patients. Bridging that gap, the authors suggest, will require combining serial ctDNA monitoring with imaging and, where feasible, repeat tissue sampling.

On the therapeutic side, the review outlines both evidence-based and investigational strategies for what the authors term niche-informed radiotherapy. Established approaches include hypoxia modification, dose escalation and altered fractionation, and combinations with DNA damage response inhibitors that disable the repair programs tolerant cells rely on. More speculative candidates target the niche itself: agents that reprogram cancer-associated fibroblasts, normalize tumor vasculature, modulate myeloid suppressor cells, or relieve immune suppression so that checkpoint blockade can act on residual disease. Senolytic strategies aimed at clearing senescence-like cells, and agents designed to push plastic persister states out of their protective equilibrium, also feature among the investigational options. The unifying principle is that candidate combinations should be validated against the specific niche dependencies of a given tumor before clinical adaptation, rather than applied indiscriminately.

The authors are equally clear about the obstacles standing between this framework and the clinic. Conceptually, tolerant niches are dynamic and heterogeneous, so static snapshots may mislead. Sampling remains a fundamental problem, since the most informative regions of a treated tumor are often inaccessible. Implementation faces the usual barriers of combination-therapy trials, toxicity management, and the absence of validated biomarkers that identify which patients carry which niche dependencies. None of these limitations, in the authors’ view, undermines the framework; they simply define the work that remains. The review, which was supported by numerous Chinese national and institutional research programs and published open access on 9 October 2026, is intended as a roadmap rather than a final verdict.

If the tolerant niche concept holds up under experimental and clinical scrutiny, its implications for oncology could be considerable. Recurrence after radiotherapy would no longer be viewed as a mysterious resurgence but as the predictable product of a documented sequence: radiation pressure, followed by the emergence of plastic residual states, followed by their stabilization within hypoxic, stromal, metabolic, and immune sanctuaries. Each step in that sequence offers an interception point, a moment when a rationally chosen combination therapy might extinguish the embers before they reignite. Turning that vision into practice will demand the longitudinal monitoring tools and niche-specific combination trials the review calls for, but it reframes one of radiotherapy’s oldest frustrations as a solvable, spatially defined problem in tumor ecology.

Subject of Research: Radioresistance and tumor recurrence through cellular plasticity and radiation-induced tolerant niches in the tumor microenvironment

Article Title: Radioresistance and tumor recurrence: cellular plasticity, tolerant niches, and therapeutic opportunities

Article References: Zhang, Y., Li, H., Lv, S., Peng, L., Meng, W., Guo, J., Lu, Y., Chen, W., Yang, W., & Peng, X. (2026). Radioresistance and tumor recurrence: cellular plasticity, tolerant niches, and therapeutic opportunities. Molecular Cancer. https://doi.org/10.1186/s12943-026-02806-3

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02806-3

Keywords: radioresistance, radiotherapy, tumor recurrence, tolerant niches, cellular plasticity, DNA damage response, tumor microenvironment, cancer stem cells, hypoxia, residual disease, spatial omics, ctDNA

The retrospective analysis drew on an institutional database of patients who had received first-time stereotactic radiosurgery for a single brain metastasis and subsequently underwent surgical resection of that same lesion, providing the gold standard of histopathological confirmation for what the imaging had shown. Thirty-six patients met the inclusion criteria. For each patient, the team manually measured tumor volumes before treatment and at three standardized post-treatment intervals: six weeks, three months, and six months. Rather than relying on a single measurement dimension, the investigators segmented three distinct tissue compartments on each scan: the contrast-enhancing volume, the FLAIR hyperintense volume, and the necrotic component. From these they derived two ratios intended to capture the relationship between edema and tumor burden, the FLAIR-to-enhancing ratio and the enhancing-to-necrotic ratio, and then modeled how each parameter evolved over time.

The volumetric data revealed a treatment effect that was real but incomplete. Mean enhancing volume declined by 28.5 percent from baseline at six weeks, 25.8 percent at three months, and 18.9 percent at six months, a pattern consistent with an initial radiosurgical response that partially attenuated over the follow-up window. The FLAIR volume followed a different and more revealing course: it fell by 16.9 percent at six weeks and 22.2 percent at three months, but then rebounded to nearly baseline, changing only 2.4 percent from the pretreatment measurement at six months. This divergence between the enhancing core and the surrounding hyperintensity is precisely why the authors argue that single-compartment assessment, the standard practice in most surveillance protocols, misses a substantial portion of the biological story unfolding after radiation.

Statistical analysis confirmed that the two compartments do not move independently. Percent changes in FLAIR volume and enhancing volume correlated significantly at both the six-week time point, with a p-value of 0.004, and the three-month time point, where the association was even stronger at p less than 0.001. In practical terms, lesions whose enhancing cores were shrinking tended to show shrinking edema as well, at least in the early post-treatment period. But the correlation broke down in the cohort’s most clinically important subgroup: the patients whose lesions ultimately failed treatment and required resection. When the investigators stratified the surgical outcomes by pathology, the FLAIR-to-enhancing ratio trended differently between radiation necrosis and recurrent tumor, and patients who developed radiation necrosis had significantly lower FLAIR volumes at six weeks compared with those whose lesions harbored recurrent tumor.

This finding carries a counterintuitive implication. Clinicians often assume that more edema signals more trouble, and in the context of symptomatic mass effect that intuition holds. But the data suggest the opposite relationship for diagnostic purposes: a lesion that retains relatively little FLAIR hyperintensity six weeks after radiosurgery, despite failing to shrink, is more likely to be radiation necrosis, whereas a non-responding lesion wrapped in substantial and persistent edema raises greater concern for viable, actively growing tumor. The biological rationale is plausible. Radiation necrosis is fundamentally a vascular and inflammatory process driven by endothelial injury, blood-brain barrier disruption, and cytokine-mediated swelling, whereas recurrent tumor generates edema through tumor-cell infiltration, angiogenic signaling, and active secretion of vascular permeability factors. The two processes stamp different volumetric signatures on the surrounding brain, and the early post-treatment window appears to be when those signatures are most distinguishable.

Beyond the diagnostic ratios, the study identified which patient and lesion characteristics shape the edema trajectory itself. Linear mixed-effects models, a statistical framework well suited to repeated measurements nested within individual patients, showed that baseline lesion size, baseline FLAIR volume, and the FLAIR-to-enhancing ratio all influenced FLAIR trajectories with p-values below 0.001. Primary cancer type and sex also emerged as significant factors, each with p-values of 0.02. These results echo a growing body of literature indicating that peritumoral edema after radiosurgery is not a uniform phenomenon but one modulated by tumor histology, systemic therapy exposure, and intrinsic lesion characteristics. Larger lesions and those with greater baseline edema burdens follow different swelling curves than small, dry lesions, which means that any future edema-based diagnostic criterion will likely need to be normalized to baseline values rather than applied as an absolute threshold.

The clinical context makes the stakes of this work concrete. Stereotactic radiosurgery has become a cornerstone of brain metastasis management precisely because it delivers ablative doses of radiation with submillimeter accuracy while sparing surrounding tissue, allowing many patients to avoid whole-brain radiation and its cognitive sequelae. But local failure rates remain nontrivial, and a meaningful fraction of patients with non-responding lesions eventually come to surgery. Prior biopsy series have shown that enlarging lesions after radiosurgery frequently turn out to be radiation necrosis rather than tumor, which means that a substantial number of patients may currently undergo resection, or receive escalating systemic therapy, for a process that was never malignant. Conversely, misattributing recurrent tumor to necrosis delays effective treatment in a population where every month of uncontrolled intracranial disease matters. Any imaging tool that sharpens this fork in the road has immediate utility.

The Yale team’s methodological choices deserve attention because they point toward how such a tool could be deployed at scale. Manual segmentation of FLAIR hyperintensity is labor-intensive and subject to interobserver variability, which has historically limited edema volumetry to research settings. The authors explicitly recommend that automated edema volumetry be incorporated into routine post-SRS surveillance, and their proposal aligns with recent pilot work demonstrating that picture archiving and communication system-integrated volumetric tools can provide peritumoral edema measurements that add information beyond standard response assessment criteria for brain metastases. If FLAIR volume trajectories can be generated automatically at each surveillance scan, the six-week and three-month ratios identified in this study could become practical decision-support metrics, flagging non-responding lesions whose edema behavior suggests recurrent tumor for earlier tissue diagnosis or intensified imaging follow-up with advanced sequences such as perfusion and diffusion MRI.

The study’s limitations are those inherent to its design. Thirty-six patients from a single institution, all of whom underwent surgery and therefore represent the more severe end of the non-response spectrum, is a modest and selected sample. The pathological endpoint was available only for lesions that failed treatment, so the volumetric signatures of well-behaved responding lesions could not be compared against a full spectrum of outcomes. The authors also note that edema trajectories are variable across patients, and the FLAIR-to-enhancing ratio trended, rather than decisively separated, the two pathological groups at all time points, with the significant six-week FLAIR volume difference being the clearest single discriminator. Validation in larger, multi-institutional cohorts, ideally with prospective edema volumetry and standardized imaging protocols, will be essential before these thresholds inform treatment decisions.

Even so, the study adds a deceptively simple idea to the post-radiosurgery toolkit: the brain around the tumor is talking, and clinicians should start listening to it quantitatively. For two decades, surveillance after radiosurgery has centered on the enhancing lesion, with edema assessed qualitatively, if at all. This analysis demonstrates that perilesional FLAIR volume follows measurable, statistically characterizable trajectories that correlate with the enhancing compartment early after treatment and diverge in diagnostically informative ways when treatment fails. As automated segmentation matures and is folded into routine radiology workflows, the humble edema measurement that radiologists have long eyeballed as background noise may become one of the most actionable numbers on the post-radiosurgery scan, helping to spare patients with radiation necrosis from unnecessary surgery while accelerating definitive intervention for those whose tumors have truly returned.

Subject of Research: Volumetric MRI analysis of edema and enhancement changes after stereotactic radiosurgery for non-responding brain metastases

Article Title: Volumetric analysis of radiographic changes after stereotactic radiosurgery for treatment of non-responding brain metastases

Article References: Rajkumar, S., Moy, H., Ji, X., Aboian, M., & Chiang, V. (2026). Volumetric analysis of radiographic changes after stereotactic radiosurgery for treatment of non-responding brain metastases. Journal of Neuro-Oncology, 180(1), Article 7. https://doi.org/10.1007/s11060-026-05824-9

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05824-9

Keywords: stereotactic radiosurgery, brain metastases, radiation necrosis, FLAIR volumetry, perilesional edema, Gamma Knife, MRI surveillance, tumor recurrence, neuro-oncology, volumetric analysis, Journal of Neuro-Oncology, Volumetric

The clinical backdrop makes the finding consequential. Hypopharyngeal squamous cell carcinoma, which arises in the region of the throat surrounding the larynx, is among the most lethal head and neck malignancies, with survival rates that have remained stubbornly poor for decades. Induction chemotherapy, typically built around the platinum drug cisplatin, is a cornerstone of treatment because it can shrink tumors enough to permit organ-preserving surgery or definitive radiation. Yet the strategy carries an inherent gamble: if resistance develops, the window for effective intervention narrows dramatically. Understanding why some tumors evolve resistance while others remain sensitive has therefore been a central question, and the mechanisms of acquired resistance to induction chemotherapy in this disease had remained incompletely mapped until now.

To interrogate that question at the genomic level, the team turned to a rare and valuable resource: paired tissue samples from nine patients with hypopharyngeal squamous cell carcinoma who had shown an initial complete or strong response to induction chemotherapy and then progressed. Because the archived paraffin-embedded specimens from both time points were available, the researchers could perform whole exome sequencing on the pre-treatment tumor and its recurrent descendant from the same patient, effectively watching tumor evolution in action. The comparison revealed that two-thirds of the patients, six of the nine, had acquired novel mutations during progression that were not detectable in their original tumors. This pattern of newly emerged variants is the genomic fingerprint of Darwinian selection, in which therapy eliminates susceptible cells and spares those rare clones carrying mutations that confer a survival advantage.

Among the newly emerged alterations, changes in three genes drew particular attention for their potential functional relevance: ENPP1, ALK, and ATP10B. But it was ENPP1 that dominated the analysis. Mutations in this gene were present in half of the six patients who had acquired new variants during progression, a striking enrichment for a single gene in so small a cohort. ENPP1 encodes ectonucleotide pyrophosphatase/phosphodiesterase 1, a membrane-bound enzyme best known in cancer biology for its ability to degrade 2’3′-cGAMP, the small signaling molecule that activates the STING pathway, a critical arm of innate immune sensing. Previous work in breast cancer and other tumor types had already implicated ENPP1 as a kind of innate immune checkpoint, allowing tumors to dampen the cGAS-STING alarm system that would otherwise flag them for immune destruction.

To move from correlation to causation, the researchers built a functional toolkit in the laboratory. Using CRISPR-Cas9-mediated knockout, they deleted ENPP1 from hypopharyngeal cancer cells and observed that its loss suppressed the malignant phenotypes that define aggressive disease, including proliferative capacity and survival under stress. Conversely, when they introduced the specific mutant variant found in the patients, a single nucleotide change designated c.2596 G > C that swaps a glutamine for a glutamic acid at position 866 of the protein, the effect reversed dramatically. Cells engineered to express mutant ENPP1 became markedly more resistant to cisplatin, the workhorse drug of induction regimens. The mutation also enhanced the enzyme’s hydrolysis of 2’3′-cGAMP, meaning the mutant protein was not merely a passive passenger but an actively more capable destroyer of the immune-activating messenger molecule.

The mechanistic thread connecting these observations runs through the STING pathway, and the study’s findings here are notable for their apparent paradox. Rather than simply shutting STING down, ENPP1 mutation was associated with sustained activation of STING, accompanied by enhanced signaling through the transcription factor NF-κB and elevated production of interleukin-6, a pro-inflammatory cytokine with well-documented roles in tumor cell survival. This matters because STING is a double-edged sword in cancer immunology. In one context, its activation recruits immune cells and sensitizes tumors to immunotherapy; in another, chronic STING engagement drives NF-κB and IL-6 signaling that promotes survival of genomically unstable cancer cells, a phenomenon documented in prior studies of chromosomally unstable cancers and triple-negative breast cancer. The Fudan team’s data suggest that in hypopharyngeal carcinoma, the mutant enzyme tilts STING signaling toward the pro-survival, inflammatory branch rather than the anti-tumor interferon response.

The in vivo evidence strengthened the case considerably. When the researchers tested the mutant ENPP1 in xenograft models, transplanting engineered tumor cells into mice, the mutation increased tumorigenic capacity, meaning tumors carrying the mutant gene grew more aggressively. Critically, those xenografts also displayed resistance to cisplatin treatment, confirming that the mutation’s effects were not artifacts of cell culture but translated into treatment failure in living tissue. Together, the in vitro and in vivo experiments establish ENPP1 mutation as a functional driver of both enhanced malignancy and chemotherapy resistance, satisfying the criteria that molecular oncologists typically demand before accepting a gene as a genuine therapeutic target rather than a bystander in tumor evolution.

The implications extend beyond cisplatin resistance into the realm of immunotherapy and treatment sequencing. Because ENPP1 mutations mediate what the authors describe as both chemotherapy resistance and immunomodulation, the finding suggests that recurrent tumors carrying these alterations may exist in a distinctly different immune microenvironment than their treatment-naive ancestors. If mutant ENPP1 reshapes STING signaling and IL-6 production, it could influence how recurrent hypopharyngeal cancers respond to immune checkpoint inhibitors, which are increasingly used in head and neck cancer. It also raises the prospect of therapeutic intervention at the ENPP1 enzyme itself; small-molecule ENPP1 inhibitors are under active development in other tumor contexts, and this study provides a rationale for evaluating them in hypopharyngeal carcinoma, potentially in combination with platinum chemotherapy to prevent or delay the emergence of resistant clones.

Caveats remain, as they must in any study of this scale. Nine patients is a small cohort, and the retrospective design means the findings require validation in larger, prospective series before ENPP1 mutation testing could enter clinical decision-making. The data underlying the study are not publicly available due to privacy and ethical considerations but can be obtained from the corresponding authors upon reasonable request, and the work was approved by the ethics committee of the Eye and ENT Hospital of Fudan University with informed consent from all participants. Still, the study’s central contribution is conceptual as much as practical: it demonstrates that the seeds of relapse are written in the genome during treatment, and it names a specific, druggable culprit. For patients whose tumors vanish on scan only to return with lethal defiance, that molecular clarity is the first step toward intercepting resistance before it takes hold.

Subject of Research: ENPP1 mutation-driven cisplatin resistance through the STING/NF-κB/IL-6 axis in hypopharyngeal squamous cell carcinoma

Article Title: From initial complete response to recurrence: ENPP1 mutation drives cisplatin resistance through STING/NF-κB/IL-6 axis in hypopharyngeal squamous cell carcinoma

Article References: Hu, C., Liu, X., Yuan, C., Zhang, L., Yang, R., Liu, R., Xiang, W., Yang, R., Hu, Q., Yu, M., Chen, J., Huang, Q., Ma, D., & Zhang, J. (2026). From initial complete response to recurrence: ENPP1 mutation drives cisplatin resistance through STING/NF-κB/IL-6 axis in hypopharyngeal squamous cell carcinoma. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03625-5

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03625-5

Keywords: ENPP1, cisplatin resistance, hypopharyngeal squamous cell carcinoma, STING pathway, NF-κB, IL-6, whole exome sequencing, tumor recurrence, induction chemotherapy, cGAMP, head and neck cancer, CRISPR-Cas9